ATE521367T1 - Flexlibler aufbau- und darreichungs-plattform von impfstoffen - Google Patents

Flexlibler aufbau- und darreichungs-plattform von impfstoffen

Info

Publication number
ATE521367T1
ATE521367T1 AT03736977T AT03736977T ATE521367T1 AT E521367 T1 ATE521367 T1 AT E521367T1 AT 03736977 T AT03736977 T AT 03736977T AT 03736977 T AT03736977 T AT 03736977T AT E521367 T1 ATE521367 T1 AT E521367T1
Authority
AT
Austria
Prior art keywords
encapsidation
nucleic acid
populations
different
vlps
Prior art date
Application number
AT03736977T
Other languages
English (en)
Inventor
Alison A Mccormick
Mark L Smith
Kenneth E Palmer
John A Lindbo
Long V Nguyen
Gregory P Pogue
Original Assignee
Kentucky Bioproc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kentucky Bioproc Llc filed Critical Kentucky Bioproc Llc
Application granted granted Critical
Publication of ATE521367T1 publication Critical patent/ATE521367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03736977T 2002-06-07 2003-06-06 Flexlibler aufbau- und darreichungs-plattform von impfstoffen ATE521367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38692102P 2002-06-07 2002-06-07
PCT/US2003/018247 WO2003103605A2 (en) 2002-06-07 2003-06-06 Flexible vaccine assembly and vaccine delivery platform

Publications (1)

Publication Number Publication Date
ATE521367T1 true ATE521367T1 (de) 2011-09-15

Family

ID=29736232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736977T ATE521367T1 (de) 2002-06-07 2003-06-06 Flexlibler aufbau- und darreichungs-plattform von impfstoffen

Country Status (8)

Country Link
US (2) US20040033585A1 (de)
EP (1) EP1545625B1 (de)
JP (1) JP2006507800A (de)
AT (1) ATE521367T1 (de)
AU (1) AU2003237528A1 (de)
CA (1) CA2486118A1 (de)
WO (1) WO2003103605A2 (de)
ZA (1) ZA200409861B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101989B1 (en) * 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
CA2490866A1 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
CA2547511A1 (en) * 2003-12-01 2005-07-28 Dow Global Technolgies Inc. Recombinant icosahedral virus like particle production in pseudomonads
EP1732615A4 (de) * 2004-03-25 2009-09-16 Kentucky Bioproc Llc Herstellung von peptiden in pflanzen als virushüllproteinfusion
BRPI0611336A2 (pt) * 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
EP2066354B1 (de) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus-impfstoffformulierungen
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2042193A1 (de) * 2007-09-28 2009-04-01 Biomay AG RNA-Impfstoffe
US9149517B2 (en) * 2007-11-02 2015-10-06 The Johns Hopkins University Multitype HPV peptide compositions and methods for treatment or prevention of human papillomavirus infection
FR2933194B1 (fr) * 2008-06-26 2010-08-13 Commissariat Energie Atomique Procede et dispositif de quantification des contaminants particulaires de surface par analyse amelioree
EP2381958A1 (de) * 2008-10-17 2011-11-02 Tallinn University Of Technology Impfstoff auf basis des kartoffelvirus-a-hüllproteins zur behandlung von melanom und verwendung davon
BR112013011069A2 (pt) * 2009-11-05 2017-03-28 Padgett Hal geração de partículas antigênicas semelhantes a virus através de ligações de proteína-proteína
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
EP4112074A1 (de) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenterale norovirus-impfstoffformulierungen
US20150274784A1 (en) * 2012-11-07 2015-10-01 Vacplanta Limted Production of an Immunogen Using a Plant Virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
BR112018003782A2 (pt) * 2015-08-27 2018-09-25 Ipsen Pharma Sas composições e métodos para o tratamento da dor
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11529413B2 (en) 2018-06-12 2022-12-20 Kbio Holdings Limited Virus and antigen purification and conjugation
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
IL279295B2 (en) 2018-06-12 2026-03-01 Kentucky Bioprocessing Inc Purification and cross-linking of virus and antigen
CN115925972A (zh) 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
ES3034151T3 (en) 2019-12-10 2025-08-13 Kbio Holdings Ltd Virus and antigen purification and conjugation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
US5667782A (en) * 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
DK0678034T3 (da) * 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
WO1995021248A1 (en) * 1994-02-03 1995-08-10 The Scripps Research Institute Method for using tobacco mosaic virus to overproduce peptides and proteins
CA2202761A1 (en) * 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5795754A (en) * 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
EP1015561B1 (de) * 1997-09-05 2006-07-19 Medimmune, Inc. Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
US6037456A (en) * 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
KR100292943B1 (ko) * 1998-03-25 2001-09-17 윤종용 디램장치의제조방법
DE69929232T2 (de) * 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CA2387921A1 (en) 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US20020127238A1 (en) 2000-06-27 2002-09-12 Leonidas Stamatatos HIV-1 vaccines and screening methods therefor
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG

Also Published As

Publication number Publication date
AU2003237528A1 (en) 2003-12-22
US20060188991A1 (en) 2006-08-24
US20040033585A1 (en) 2004-02-19
EP1545625A4 (de) 2008-05-07
US7939318B2 (en) 2011-05-10
JP2006507800A (ja) 2006-03-09
EP1545625B1 (de) 2011-08-24
EP1545625A2 (de) 2005-06-29
WO2003103605A2 (en) 2003-12-18
CA2486118A1 (en) 2003-12-18
ZA200409861B (en) 2006-07-26
WO2003103605A3 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
ATE521367T1 (de) Flexlibler aufbau- und darreichungs-plattform von impfstoffen
Afrough et al. Emerging viruses and current strategies for vaccine intervention
Liu et al. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection
Bansal et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
EE200300331A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
NO20025402D0 (no) Modifiserte ES-celler og ES-spesifikt gen
DK1448229T3 (da) Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
ATE365205T1 (de) Virale partikel, die nach infektion durch humanes cytomegalovirus freigesetzt werden und ihre verwendung als impfstoff
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
WO2002064757A3 (en) Influenza viruses with enhanced transcriptional and replicational capacities
WO2001087350A3 (en) Treatment of human papillomavirus (hpv)-infected cells
WO2002088328A8 (en) Method for generating highly active human dendritic cells from monocytes
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
ID27206A (id) Generasi produk-produk perbanyakan gena dari protein-protein fusi simerik melalui pemutusan endoprotease ubikuitus
WO2005091753A3 (en) Flexible vaccine assembly and vaccine delivery platform
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
Mufamadi et al. Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2
Mata et al. Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 C
US20190000994A1 (en) Method For Inducing Antitumor Immunity Using Sindbis Viral Vectors And Tumor Associated Antigens
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
MY182347A (en) Genes encoding major capsid protein l1 of human papilloma virus and use of the same
EP1712243A4 (de) Gentherapie gegen tumoren mit minus-strang-rna-virusvektoren, die für immunstimulatorische zytokine codieren
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
Behboudi et al. Crimean-Congo hemorrhagic fever virus vaccine: past, present, and future
Wang et al. Trivalent mRNA vaccine against SARS-CoV-2 and variants with effective immunization

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties